Skye Bioscience, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego, april 30, 2024 (globe newswire) -- skye bioscience, inc. (nasdaq: skye) (“skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present two posters at the association for research in vision and ophthalmology (arvo) 2024 annual meeting being held may 5-9, 2024, in seattle, washington.

San diego, april 23, 2024 (globe newswire) -- skye bioscience, inc. (nasdaq: skye) (“skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that chief executive officer & chair punit dhillon and other members of skye's executive team will present the company and its programs in obesity and glaucoma at the following investment conferences:

San diego, april 10, 2024 (globe newswire) -- skye bioscience, inc. (otcqb: skye) (“skye” or the "company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the company has received approval to list its common stock on the nasdaq global market® stock exchange ("nasdaq"). the company's common stock is expected to commence trading on nasdaq at the market open on thursday, april 11th, 2024, under the ticker symbol "skye". the company's common stock will no longer trade on the over-the-counter securities market.

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 san diego, california--(newsfile corp. - march 11, 2024) - skye bioscience, inc. (otcqb: skye) (the company), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it has entered into a securities purchase agreement for the sale of 4,000,000 shares of its common stock at $10.00 per share to certain investors in a private placement (the "pipe") to certain qualified institutional buyers. gross proceeds from the pipe are expected to be $40 million before deducting any placement agent fees and offering-related expenses.

San diego, march 04, 2024 (globe newswire) -- skye bioscience, inc. (otcqb: skye) ("skye" or the "company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with a focus on obesity and ocular indications, is pleased to announce the appointment of dr. annalisa jenkins, mbbs, frcp, to the company's board of directors. dr. jenkins' esteemed career spans more than 25 years in the global pharmaceutical, biotechnology and life science industry. she has broad experience in building and leading teams and developing strategies that have resulted in the advancement of new products across multiple disease areas from discovery through to clinical development, regulatory approval and commercialization worldwide.

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye's executive team will present the company and its programs in obesity and glaucoma at the following investment conferences:

Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

Personalized health screening from a “smart toilet”

San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its glaucoma program at two ophthalmology-focused conferences. Company executives will introduce SBI-100 Ophthalmic Emulsion, Skye's first-in-class CB1 agonist, highlight recent Phase 1 data, and outline details of its Phase 2a clinical study, which will start dosing shortly.

San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, announced today that it will present a company overview at the H.C. Wainwright 25th 3rd Annual Global Investment Conference being held virtually.

Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ophthalmic-focused contract research organization (CRO) for its planned Phase 2a study of SBI-100 OE for glaucoma and hypertension.  "We have a high level of confidence in Lexitas' expertise to support our Phase 2a study in the United States," Skye chief development officer Tu Diep said in a statement.

Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee (SRC) based on dosing of the first cohort of eight healthy participants of its phase 1 study of SBI-100 Ophthalmic Emulsion (OE).  SBI-100 OE is focused on developing a treatment for glaucoma.

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) application for SBI-100 Ophthalmic Emulsion (OE), a synthetic cannabinoid derivative that targets the CB1 receptor, which plays a key role in managing intraocular pressure. The company can now initiate clinical trials in the US, including its planned Phase 2 study for primary open-angle glaucoma or ocular hypertension in the first half of 2023.

Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 Ophthalmic Emulsion (OE) in the first cohort of healthy participants in the single ascending dose (SAD) part of its Phase 1 study being conducted by CMAX Clinical Research in Adelaide, Australia. "This first-in-human Phase 1 trial is a significant milestone for Skye and SBI-100 Ophthalmic Emulsion.